Drug Approvals Hit a Seven-Year High in 2011 on Improved Data

U.S. approvals of new drugs hit a seven-year high last year as pharmaceutical companies responded to regulators’ demands for better safety data and avoided last-minute requests for more information.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.